Page 48 - JCTR-9-4

264 Ali et al. | Journal of Clinical and Translational Research 2023; 9(4): 261-264
Dent 2013;4:227-30. [10] Michou L, Brown JP. Emerging Strategies and Therapies
[8] Singer FR, Bone HG 3 , Hosking DJ, Lyles KW, for Treatment of Paget’s Disease of Bone. Drug Des Devel
rd
Murad MH, Reid IR, et al. Lyles, Paget’s Disease of Bone: Ther 2011;5:225-39.
An Endocrine Society Clinical Practice Guideline. J Clin [11] Durgia H, Sahoo J, Kamalanathan S, Palui R, Kumar R,
Endocrinol Metab2014;99:4408-22. Halanaik D, et al. Response to Zoledronic Acid in Patients
with Active Paget’s Disease of Bone: A Retrospective
[9] Aransiola CO, Ipadeola A. Asymptomatic Paget’s Disease Study. Indian J Endocrinol Metab 2019;23:117-21.
of Bone in a 62-Year-Old Nigerian Man: Three Years Post- [12] De Castro GR, Buss ZD, Rosa JS, Facchin BM, Fröde TS.
Alendronate Therapy. Endocrinol Diabetes Metab Case Evaluation of Bone Metabolism Biomarkers in Paget’s
Rep 2016;2016:160005. Disease of Bone. Cureus 2019;11:e4791.

Publisher’s note
AccScience Publishing remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.
DOI: http://dx.doi.org/10.18053/jctres.09.202304.22-00186